Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

SELL
$0.4 - $4.27 $6,759 - $72,154
-16,898 Reduced 99.76%
41 $0
Q2 2022

Aug 15, 2022

BUY
$0.56 - $1.29 $8,734 - $20,121
15,598 Added 1163.16%
16,939 $10,000
Q1 2022

May 12, 2022

SELL
$0.72 - $1.86 $4,093 - $10,574
-5,685 Reduced 80.91%
1,341 $2,000
Q4 2021

Feb 14, 2022

SELL
$1.3 - $3.17 $12,010 - $29,287
-9,239 Reduced 56.8%
7,026 $10,000
Q3 2021

Nov 15, 2021

BUY
$2.91 - $4.5 $35,263 - $54,531
12,118 Added 292.21%
16,265 $48,000
Q2 2021

Aug 16, 2021

BUY
$4.15 - $6.3 $1,195 - $1,814
288 Added 7.46%
4,147 $19,000
Q1 2021

May 17, 2021

SELL
$5.51 - $9.42 $8,242 - $14,092
-1,496 Reduced 27.94%
3,859 $23,000
Q4 2020

Feb 16, 2021

SELL
$3.42 - $6.36 $102,056 - $189,788
-29,841 Reduced 84.79%
5,355 $28,000
Q3 2020

Nov 16, 2020

BUY
$2.94 - $12.43 $86,441 - $365,466
29,402 Added 507.46%
35,196 $121,000
Q2 2020

Aug 13, 2020

BUY
$5.28 - $9.67 $24,266 - $44,443
4,596 Added 383.64%
5,794 $51,000
Q1 2020

May 15, 2020

SELL
$5.0 - $7.6 $25,370 - $38,562
-5,074 Reduced 80.9%
1,198 $7,000
Q4 2019

Feb 07, 2020

SELL
$5.99 - $8.38 $6,798 - $9,511
-1,135 Reduced 15.32%
6,272 $45,000
Q3 2019

Nov 05, 2019

BUY
$5.62 - $9.63 $41,627 - $71,329
7,407 New
7,407 $45,000
Q2 2019

Aug 13, 2019

SELL
$7.59 - $10.21 $49,737 - $66,906
-6,553 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$7.65 - $16.66 $50,130 - $109,172
6,553 New
6,553 $53,000
Q4 2018

Feb 14, 2019

SELL
$10.76 - $17.25 $10,609 - $17,008
-986 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$14.34 - $22.97 $14,139 - $22,648
986 New
986 $16,000

Others Institutions Holding UBX

# of Institutions
1
Shares Held
4.41M
Call Options Held
0
Put Options Held
0

About Unity Biotechnology, Inc.


  • Ticker UBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,036,200
  • Market Cap $14M
  • Description
  • Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...
More about UBX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.